SNCA and Parkinson disease: Because this activation leads to a reduction in mitochondrial stress and α-synuclein toxicity, two hallmarks of PD, ATP13A2 has been proposed as a therapeutic target.34 Ultimately, the exploration of the similarities and cross-talks between these three modules suggests further investigation of the candidate PD gene ATP13A2.